|Systematic (IUPAC) name|
|Mol. mass||253.34 g/mol|
- Pharmacology 1
- Other uses 2
- See also 3
- References 4
- External links 5
The dextrorotary (R)-(+)-enantiomer is the most pharmacologically active, although a variety of related derivatives have been studied. Anecdotally, the dextrorotary enantiomer is orally active in the 2 mg - 5 mg range with a duration of 5–8 hours. The effects are said to be similar to other NDRIs, producing mild stimulation (at least in relation to substances like methylphenidate or cocaine) which is productive for working or studying, but with relatively little euphoria. Similar drugs to diphenylprolinol include pipradrol, desoxypipradrol, and to a lesser extent, methylphenidate.
There have been indications from detailed reports posted on Internet forums dedicated to researching such compounds that diphenylprolinol may not be as benign as its mild effects seem to suggest. At higher doses and with more frequent administration, its effects on dopamine can become significant enough for binging and addiction to enter the picture. Several large overdoses requiring hospitalization have been reported, possibly related to addiction issues. It is advisable to exercise caution when administering this compound, even for occasional use, as most dopamine reuptake inhibitors are addictive.
Side effects including chest pain (suggestive of possible cardiovascular toxicity) have been seen following recreational use of diphenylprolinol, although it was combined with glaucine in a party pill product ("Head Candy" brand), thus making it impossible to say for certain which drug was responsible.
Diphenylprolinol can be used to prepare the chiral
- Synthesis of diphenyl-2-pyrrolidinyl-methanol and diphenyl-2-pyrrolidinyl-methane
- Synthesis information of D2PM
- Wood DM et al, Detection of the novel recreational drug Diphenyl-2-pyrrolidinemethanol (D2PM) sold legally in combination with 1-Benzylpiperzaine (BZP). Clinical Toxicology 2008; 46:393.
- Davies S. Drug Trends and New Designer Drugs. St George's University of London. 6th November 2008.
- Paul F. Jackson et al. Pharmaceutical compositions and methods for treating compulsive disorders using pyrrolidine derivatives. US Patent 5295666
- Lidder, S; Dargan, P; Sexton, M; Button, J; Ramsey, J; Holt, D; Wood, D (2008). "Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol D2PM)". Journal of Medical Toxicology 4 (3): 167–9.
- Corey, E. J.; Bakshi, R. K.; Shibata S., (1987). "Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines Mechanism and synthetic implications".
- 2-Diphenylmethylpyrrolidine (Desoxy-diphenylprolinol)
- Corey-Bakshi-Shibata reduction
- CBS catalyst